Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 9;12(19):6420.
doi: 10.3390/jcm12196420.

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

İbrahim Vedat Bayoğlu  1 , Javid Hüseynov  1 , Alper Topal  2 , Nadiye Sever  1 , Nargiz Majidova  1 , Abdussamet Çelebi  1 , Alper Yaşar  1 , Rukiye Arıkan  1 , Selver Işık  1 , Muhammet Bekir Hacıoğlu  2 , Özlem Ercelep  1 , Murat Sarı  1 , Bülent Erdoğan  2 , İlhan Hacıbekiroğlu  3 , Sernaz Topaloğlu  2 , Osman Köstek  1 , İrfan Çiçin  2
Affiliations

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

İbrahim Vedat Bayoğlu et al. J Clin Med. .

Abstract

Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting.

Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan-Meier and Cox regression analysis.

Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS.

Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.

Keywords: IMDC model; PNI; adjusted PNI-IMDC model; metastatic RCC; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Adjusted PNI-IMDC model for predicting PFS and OS.
Figure 2
Figure 2
ROC curve analysis of the models in regard to both PFS and OS.
Figure 3
Figure 3
Kaplan–Meier curve for PFS based on classic IMDC and adjusted PNI-IMDC model.
Figure 4
Figure 4
Overall survival curve using Cox regression analysis according to adjusted PNI-IMDC model.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017;67:7–30. doi: 10.3322/caac.21387. - DOI - PubMed
    1. Leibovich B.C., Lohse C.M., Crispen P.L., Boorjian S.A., Thompson R.H., Blute M.L., Cheville J.C. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol. 2010;183:1309–1315. doi: 10.1016/j.juro.2009.12.035. - DOI - PubMed
    1. Howlader N.N.A., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., Chen H.S., et al. SEER Cancer Statistics, Review, Based on November 2016 SEER Data Submission, Posted to the SEER Web Site aNCI, Bethesda MAahscgc. [(accessed on 30 August 2023)]; Available online: https://seer.cancer.gov/csr/1975_2014/
    1. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2002;20:289–296. doi: 10.1200/JCO.2002.20.1.289. - DOI - PubMed
    1. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., Eigl B.J., Ruether J.D., Cheng T., North S., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009;27:5794–5799. doi: 10.1200/JCO.2008.21.4809. - DOI - PubMed

LinkOut - more resources